A meta-analysis conducted by Melin et al. (2024) involving 13 RCTs stated that metformin should remain the first-line insulin sensitizer for managing body weight and other metabolic issues in adult PCOS patients because it was superior to rosiglitazone or pioglitazone [75], whereas Abdalla et al. (2024) (24 RCTs, 975 subjects) reported that rosiglitazone and pioglitazone increased weight and BMI more significantly than the placebo and metformin. The gene discussed is INS; the disease is polycystic ovary syndrome.